Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development.

× No keyword cloud information.

12 in total

1. Future prospects for biomarkers of alcohol consumption and alcohol-induced disorders.

Authors: Willard M Freeman; Kent E Vrana
Journal: Alcohol Clin Exp Res Date: 2010-04-05 Impact factor: 3.455

2. Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

Authors: Donald R Stanski; Malcolm Rowland; Lewis B Sheiner
Journal: J Pharmacokinet Pharmacodyn Date: 2005-11-07 Impact factor: 2.745

3. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Authors: Meindert Danhof; Gunnar Alvan; Svein G Dahl; Jochen Kuhlmann; Gilles Paintaud
Journal: Pharm Res Date: 2005-08-24 Impact factor: 4.200

4. Translational medicine: can it really facilitate the transition of research "from bench to bedside"?

Authors: Martin Wehling
Journal: Eur J Clin Pharmacol Date: 2005-12-13 Impact factor: 2.953

Review 5. Translational research in central nervous system drug discovery.

Authors: Orest Hurko; John L Ryan
Journal: NeuroRx Date: 2005-10

Review 6. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors: Adam Cohen
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447

7. Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury model.

Authors: Peter M Grace; Daniel Hurley; Daniel T Barratt; Anna Tsykin; Linda R Watkins; Paul E Rolan; Mark R Hutchinson
Journal: J Neurochem Date: 2012-07-09 Impact factor: 5.372

8. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

Authors: Magdalena Zajac; Gonzalo Gomez; Javier Benitez; Beatriz Martínez-Delgado
Journal: BMC Med Genomics Date: 2010-10-04 Impact factor: 3.063

9. Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: first-in-man study of BAY 63-9044, a new 5-HT1A-receptor agonist with dopamine agonistic properties.

Authors: Georg Wensing; Claus Haase; Erich Brendel; Michael Friedrich Böttcher
Journal: Eur J Clin Pharmacol Date: 2007-09-25 Impact factor: 2.953

10. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Authors: Paul M Barr; Thomas P Miller; Jonathan W Friedberg; Derick R Peterson; Andrea M Baran; Megan Herr; Catherine M Spier; Haiyan Cui; Denise J Roe; Daniel O Persky; Carla Casulo; Jamie Littleton; Mark Schwartz; Soham Puvvada; Terry H Landowski; Lisa M Rimsza; Robert T Dorr; Richard I Fisher; Steven H Bernstein; Margaret M Briehl
Journal: Blood Date: 2014-07-11 Impact factor: 22.113